SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$SNDX

Recent Analyst Ratings for
$SNDX

$SNDX
Press Releases

$SNDX
Insider Purchases

$SNDX
Analyst Ratings

$SNDX
Insider Trading

$SNDX
SEC Filings

$SNDX
FDA approvals

$SNDX
Leadership Updates

$SNDX
Large Ownership Changes

$SNDX
Financials

Recent Analyst Ratings for $SNDX

Recent Analyst Ratings for $SNDX

$SNDX Press Releases

$SNDX Insider Purchases

$SNDX Analyst Ratings

$SNDX Insider Trading

$SNDX SEC Filings

$SNDX FDA approvals

$SNDX Leadership Updates

$SNDX Large Ownership Changes

$SNDX Financials

Recent Analyst Ratings for
$SNDX

Recent Analyst Ratings for
$SNDX

$SNDX
Press Releases

$SNDX
Insider Purchases

$SNDX
Analyst Ratings

$SNDX
Insider Trading

$SNDX
SEC Filings

$SNDX
FDA approvals

$SNDX
Leadership Updates

$SNDX
Large Ownership Changes

$SNDX
Financials

Crush Q1 2026 with the Best AI Superconnector

Crush Q1 2026 with the Best AI Superconnector

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

H.C. Wainwright resumed coverage on Syndax Pharmaceuticals with a new price target

Stifel resumed coverage on Syndax Pharmaceuticals with a new price target

Guggenheim resumed coverage on Syndax Pharmaceuticals with a new price target

Chief Executive Officer Metzger Michael A sold $360,819 worth of shares (17,159 units at $21.03), decreasing direct ownership by 3% to 491,690 units (SEC Form 4)

Chief Financial Officer Goldan Keith A. sold $71,705 worth of shares (3,410 units at $21.03), decreasing direct ownership by 2% to 140,429 units (SEC Form 4)

Chief Executive Officer Metzger Michael A was granted 217,600 shares and sold $152,835 worth of shares (7,412 units at $20.62), increasing direct ownership by 70% to 508,849 units (SEC Form 4)

SEC Form SCHEDULE 13G filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Crush Q1 2026 with the Best AI Superconnector

Crush Q1 2026 with the Best AI Superconnector

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

H.C. Wainwright resumed coverage on Syndax Pharmaceuticals with a new price target

Stifel resumed coverage on Syndax Pharmaceuticals with a new price target

Guggenheim resumed coverage on Syndax Pharmaceuticals with a new price target

Chief Executive Officer Metzger Michael A sold $360,819 worth of shares (17,159 units at $21.03), decreasing direct ownership by 3% to 491,690 units (SEC Form 4)

Chief Financial Officer Goldan Keith A. sold $71,705 worth of shares (3,410 units at $21.03), decreasing direct ownership by 2% to 140,429 units (SEC Form 4)

Chief Executive Officer Metzger Michael A was granted 217,600 shares and sold $152,835 worth of shares (7,412 units at $20.62), increasing direct ownership by 70% to 508,849 units (SEC Form 4)

SEC Form SCHEDULE 13G filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

10/5/23 12:23:50 PM ET

$SNDX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNDX alert in real time by email

SC 13G/A 1 d542507dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Syndax Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

87164F105

(CUSIP Number)

October 3, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105


Item 1(a).		Name of Issuer: Syndax Pharmaceuticals, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are: Frazier Life Sciences Public Fund, L.P. (“FLSPF”) FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”) FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences XI, L.P. (“FLS XI”) FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences X, L.P. (“FLS X”) FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper (“Topper”) Patrick J. Heron (“Heron”) Albert Cha (“Cha”) James Brush (“Brush”) Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 70 Willow Road, Suite 200 Menlo Park, CA 94025


Item 2(c).	Citizenship:

	Entities:	FLSPF	- Delaware, U.S.A.
		FHMLSP, L.P.	- Delaware, U.S.A.
		FHMLSP, L.L.C.	- Delaware, U.S.A.
		FLSPOF	- Delaware, U.S.A.
		FHMLSP Overage, L.P.	- Delaware, U.S.A.
		FHMLSP, L.L.C.	- Delaware, U.S.A.
		FLS XI	- Delaware, U.S.A.
		FHMLS XI, L.P.	- Delaware, U.S.A.
		FHMLS XI, L.L.C.	- Delaware, U.S.A.
		FLS X	- Delaware, U.S.A.
		FHMLS X, L.P.	- Delaware, U.S.A.
		FHMLS X, L.L.C.	- Delaware, U.S.A.

	Individuals:	Topper	- United States Citizen
		Heron	- United States Citizen
		Cha	- United States Citizen
		Brush	- United States Citizen
		Estes	- United States Citizen


Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 87164F105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G amendment.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: October 5, 2023	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner By: FHMLSP Overage, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner By: FHMLS XI, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS XI, L.P. By: FHMLS XI, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: October 5, 2023	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	By:	*
		James N. Topper

Date: October 5, 2023	By:	*
		Patrick J. Heron

Date: October 5, 2023	By:	**
		Albert Cha

Date: October 5, 2023	By:	**
		James Brush

Date: October 5, 2023	By:	***
		Daniel Estes

Date: October 5, 2023	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index

Exhibit A - Agreement regarding filing of joint Schedule 13G.

Get the next $SNDX alert in real time by email

Recent Analyst Ratings for

$SNDX

Date	Price Target	Rating	Analyst
10/16/2025	$40.00	Buy	H.C. Wainwright
9/10/2025	$44.00	Buy	Stifel
9/4/2025	$34.00	Buy	Guggenheim
8/5/2025	$43.00 → $56.00	Buy	BTIG Research
7/10/2025	$18.00	Buy	Goldman
10/24/2024	$37.00	Buy	UBS
6/28/2024	$37.00	Buy	Jefferies
1/31/2024	$36.00 → $23.00	Sector Outperform → Sector Perform	Scotiabank

More analyst ratings

10/5/23 12:23:50 PM ET

$SNDX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNDX alert in real time by email

SC 13G/A 1 d542507dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Syndax Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

87164F105

(CUSIP Number)

October 3, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105

CUSIP No. 87164F105


Item 1(a).		Name of Issuer: Syndax Pharmaceuticals, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are: Frazier Life Sciences Public Fund, L.P. (“FLSPF”) FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”) FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences XI, L.P. (“FLS XI”) FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences X, L.P. (“FLS X”) FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper (“Topper”) Patrick J. Heron (“Heron”) Albert Cha (“Cha”) James Brush (“Brush”) Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 70 Willow Road, Suite 200 Menlo Park, CA 94025


Item 2(c).	Citizenship:

	Entities:	FLSPF	- Delaware, U.S.A.
		FHMLSP, L.P.	- Delaware, U.S.A.
		FHMLSP, L.L.C.	- Delaware, U.S.A.
		FLSPOF	- Delaware, U.S.A.
		FHMLSP Overage, L.P.	- Delaware, U.S.A.
		FHMLSP, L.L.C.	- Delaware, U.S.A.
		FLS XI	- Delaware, U.S.A.
		FHMLS XI, L.P.	- Delaware, U.S.A.
		FHMLS XI, L.L.C.	- Delaware, U.S.A.
		FLS X	- Delaware, U.S.A.
		FHMLS X, L.P.	- Delaware, U.S.A.
		FHMLS X, L.L.C.	- Delaware, U.S.A.

	Individuals:	Topper	- United States Citizen
		Heron	- United States Citizen
		Cha	- United States Citizen
		Brush	- United States Citizen
		Estes	- United States Citizen


Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 87164F105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G amendment.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: October 5, 2023	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
	By: FHMLSP Overage, L.P., its General Partner By: FHMLSP Overage, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP OVERAGE, L.P.
	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner By: FHMLS XI, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS XI, L.P. By: FHMLS XI, L.L.C., its General Partner


	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: October 5, 2023	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: October 5, 2023	By:	*
		James N. Topper

Date: October 5, 2023	By:	*
		Patrick J. Heron

Date: October 5, 2023	By:	**
		Albert Cha

Date: October 5, 2023	By:	**
		James Brush

Date: October 5, 2023	By:	***
		Daniel Estes

Date: October 5, 2023	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index

Exhibit A - Agreement regarding filing of joint Schedule 13G.

Get the next $SNDX alert in real time by email

Recent Analyst Ratings for

$SNDX

Date	Price Target	Rating	Analyst
10/16/2025	$40.00	Buy	H.C. Wainwright
9/10/2025	$44.00	Buy	Stifel
9/4/2025	$34.00	Buy	Guggenheim
8/5/2025	$43.00 → $56.00	Buy	BTIG Research
7/10/2025	$18.00	Buy	Goldman
10/24/2024	$37.00	Buy	UBS
6/28/2024	$37.00	Buy	Jefferies
1/31/2024	$36.00 → $23.00	Sector Outperform → Sector Perform	Scotiabank

More analyst ratings

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware